Enable job alerts via email!
Boost your interview chances
Create a job specific, tailored resume for higher success rate.
An established industry player is seeking an internationally recognized leader to head their Section of Transplantation and Cellular Therapy. This pivotal role involves overseeing clinical and research initiatives, expanding pediatric hematopoietic stem cell transplantation programs, and conducting innovative research in gene and cell therapies. Join a world-class institution renowned for its top-ranked pediatric hematology-oncology program, where you will have the opportunity to make a significant impact in advancing cutting-edge treatments for pediatric disorders. This is a unique chance to lead in a dynamic environment committed to excellence and diversity.
The University of Southern California (USC), founded in 1880, is the largest private employer in Los Angeles. As an employee, you will join a world-class research university and be part of the "Trojan Family," comprising faculty, students, and staff.
The Cancer and Blood Disease Institute (CBDI) at Children's Hospital Los Angeles (CHLA) and the Division of Hematology-Oncology within USC's Keck School of Medicine are seeking an internationally recognized leader to serve as Head of the Section of Transplantation and Cellular Therapy and hold the Endowed Chair in Transplantation and Cellular Therapy. This role involves overseeing clinical and research activities and expanding programs in pediatric hematopoietic stem cell transplantation and cancer cell therapy. The candidate will conduct research and advance a leading program integrating laboratory and clinical science to develop innovative hematopoietic transplantation, gene, and cell therapies. The position includes membership at USC Norris Comprehensive Cancer Center and an academic appointment at USC Keck School of Medicine at the level of Associate Professor or Professor, commensurate with experience and training.
The CBDI's Transplantation and Cellular Therapy Program performs approximately 80-100 transplants annually for various pediatric disorders, including malignant, hematological, immunodeficiency, and genetic diseases, along with 20-40 CAR T-cell therapies each year. The program features a cell processing laboratory, a cGMP facility, and accreditation by FACT and NMDP.
The CBDI is the largest and top-ranked pediatric hematology-oncology program in the western U.S., ranked #7 by U.S. News & World Report (2021-2022). It has a robust clinical trials operation supporting hematology, oncology, and transplantation programs, with three international clinical trials consortia headquartered within the CBDI: TACL, NANT, and CHAT. The CBDI also participates in additional leading consortia, including PTCTC. Investigators conduct extensive bench-to-bedside research, with FY20 research funding totaling $59 million, including $17 million in new awards. The CBDI hosts an ACGME-accredited pediatric hematology-oncology fellowship and advanced subspecialty fellowships in Transplantation/Cellular Therapy, Coagulation, Neuro-Oncology, and AYA Oncology.
Support in administration, research, staff, resources, and infrastructure will be provided. CHLA and USC are equal opportunity employers committed to diversity. Applicants from underrepresented groups are especially encouraged.
For inquiries, contact:
Alan S. Wayne, M.D.
Director, Cancer and Blood Disease Institute
Head, Division of Hematology-Oncology
Vice Chair, Department of Pediatrics
Children's Hospital Los Angeles
Associate Director, USC Norris Comprehensive Cancer Center
Professor of Pediatrics and Medicine, Keck School of Medicine
University of Southern California
Alfred E. Mann Family Foundation Chair in Cancer Research
Email: awayne@chla.usc.edu
USC values diversity and is committed to equal opportunity employment. Women, men, members of all racial and ethnic groups, people with disabilities, and veterans are encouraged to apply.